These 2 Biotech Stocks Still Have Upside

The biotech sector has had a big move since the beginning of last week. Several multi-billion dollar acquisitions with big buyout premiums and good earnings reports have ignited the "animal spirits" in this high-beta space. Some of the major biotech indices have finally surpassed all-time peaks last seen in July of 2015, just before the sector went into a big bear market that took many of these indices down 40% peak to trough.

The ascent has been fairly broad-based, with both the industry giants and small developmental firms participating. After lagging the market badly for three years, Gilead Sciences (GILD) seems to have finally broken out of its funk. The purchase of CAR-T concern Kite Pharma (KITE) at the end of August and the approval of that company's primary drug candidate Yescarta soon thereafter has changed the narrative on the company. Its stock is rapidly nearing the $90 level, something it hasn't done in nearly two years....363 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.

Read the full story and get access to the Real Money Pro trading floor.

There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.

Already a Subscriber? Please login.

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.